Osnat Bohana‐Kashtan

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Bruno Bockorny, Valerya Semenisty, Teresa Macarulla et al. · Nature Medicine · 2020 · 533 citations

Medicine, Oncology, Pharmacology +11

High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias

Sebastien Morisot, Alan S. Wayne, Osnat Bohana‐Kashtan et al. · Leukemia · 2010 · 56 citations · Full text

Medicine, Hematology, Oncology +17

Long-Term Efficacy of GMP Grade Xeno-Free hESC-Derived RPE Cells Following Transplantation

Trevor J. McGill, Osnat Bohana‐Kashtan, Jonathan Stoddard et al. · Translational Vision Science & Technology · 2017 · 56 citations · Full text

Medicine, Cell Biology, Ophthalmology +17

Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement-mediated lysis

Osnat Bohana‐Kashtan, Lorenzo A. Pinna, Zvi Fishelson · European Journal of Immunology · 2005 · 45 citations · Full text

Life Sciences, Cell Biology, Immunology +13

BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study

Gautam Borthakur, Yishai Ofran, Martin S. Tallman et al. · Cancer · 2020 · 39 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16